

Referral Status:	MRN:
<input type="checkbox"/> New referral	<input type="checkbox"/> Order change
<input type="checkbox"/> Order Renewal	
Patient preferred clinic:	

**Tocilizumab Unspecified Plan of Treatment for Rheumatology**

**PATIENT DEMOGRAPHICS:**

Patient Name: \_\_\_\_\_  
 Patient's Phone: \_\_\_\_\_ Address: \_\_\_\_\_  
 Date of Birth: \_\_\_\_\_ City, State, Zip: \_\_\_\_\_  
 Height in inches: \_\_\_\_\_ Weight: \_\_\_\_\_ LB or \_\_\_\_\_ KG Gender: \_\_\_\_\_ Allergies: \_\_\_\_\_ See list  NKDA

**DIAGNOSIS: (PLEASE COMPLETE 2<sup>ND</sup> AND 3<sup>RD</sup> DIGITS TO COMPLETE ICD 10 FOR BILLING)**

M05._____ - Rheumatoid Arthritis with Rheumatoid factor	M31.6 - Other Giant Cell Arteritis
M06._____ - Rheumatoid Arthritis without Rheumatoid factor	M31.5 - Giant cell Arthritis with Polymyalgia Rheumatica
_____ - Other:	

**REQUESTED DOCUMENTATION: PREVIOUS ADMINISTRATION: HAS THIS PATIENT TAKEN THIS MEDICATION BEFORE?**

1 Insurance information	IF NO:	IF YES:
2 Most recent History & Physical	PLEASE STATE	LAST INFUSION DATE:
3 Full medication list / Tried and failed therapies	REQUIRED WASHOUT	NEXT INFUSION DATE:
4 <b>REQUIRED:</b> TB screening for new start	FROM PREVIOUS	<b>IF ORDER CHANGE:</b>
5 HBV screening/labs as required by payor	THERAPY:	<b>Continue current order until insurance approved</b>
6 Recent CBC with diff and LFTs		

**MEDICATION ORDERS:**

**PREMEDICATION TO BE ADMINISTERED 30 MINUTES PRIOR TO ADMINISTRATION AS SELECTED**

NOTE: Patient may be ineligible to receive tocilizumab if receiving antibiotics for active infectious process, antifungal therapy, active fever and/or suspected infection, new-onset or deterioration neurological changes, new-onset abdominal symptoms, and/or surgery.

<b>IV</b>	Diphenhydramine	25mg	50mg		<b>PO</b>	Acetaminophen	325mg	500mg	650mg	1000mg
	Methylprednisolone	40mg	125mg	Other:		Famotidine	20mg	40mg		
	Famotidine	20mg	40 mg			Diphenhydramine	25mg	50mg		
	Other:					Fexofenadine	60mg	180mg		
					Cetirizine	10mg				
					Loratadine	10mg				
					Other:					

**SPECIFIC MEDICATION:**

<input type="checkbox"/> Actemra®	<input type="checkbox"/> <b>Any tocilizumab biosimilar may be used according to payer guidelines</b>
<input type="checkbox"/> Tyenne®	

**LAB ORDERS:**

CBC with diff, platelets, ALT and AST prior to first dose, at 2nd infusion, and then every 12 weeks.

**LAB PARAMETERS:**

On Initiation: ANC > 2000mm<sup>3</sup>; AST/ALT < 1.5 x ULN  
 Maintenance: If ANC is 500 to 1000 cells/mm<sup>3</sup>, hold dose and notify referring MD. When ANC > 1000 cells/mm<sup>3</sup> therapy may be resumed. If ANC < 500 cells/mm<sup>3</sup>, then discontinue and notify referring MD. If Platelet count 50,000 to 100,000 cells/mm<sup>3</sup>, hold dose. When platelet count is > 100,000 cells/mm<sup>3</sup>, therapy may be resumed. If Platelet count is < 50,000 cells/mm<sup>3</sup>, then discontinue and notify referring MD. If AST/ALT are > 3-5 x upper limit normal HOLD dose and notify referring MD

**Tocilizumab doses exceeding 800mg are not recommended.**

Prescriber confirms that the patient has been evaluated and screened for the presence of hepatitis B virus (HBV) prior to initiating treatment.  
 Prescriber to monitor patient for symptoms of HBV and TB infection and reactivation as clinically appropriate.

Refills x 12 months unless noted otherwise here:

**LINE USE/CARE ORDERS:**

Start PIV/Access CVC  
 Flush device per facility standard flushing procedure  
 Provide nursing care per Palmetto Infusion Nursing Procedures and post procedure observation if indicated

**ADVERSE REACTION & ANAPHYLAXIS ORDERS:**

Administer acute infusion and anaphylaxis medications per Palmetto Infusion standing adverse reaction orders, which can be found at our website.

**PRESCRIBER INFORMATION:**

PROVIDER NAME: \_\_\_\_\_ PHONE: \_\_\_\_\_  
 ADDRESS: \_\_\_\_\_ FAX: \_\_\_\_\_  
 CITY, STATE, ZIP: \_\_\_\_\_ NPI: \_\_\_\_\_

**PRESCRIBER SIGNATURE: (No stamp signatures)**

**DATE**

Dispense as written/Brand medically necessary	Substitution permitted